Zai Lab And argenx Get Approval For Efgartigimod Alfa SC Injection For Generalized Myasthenia Gravis In China

7/16/24 1:13:51 AM ET

$ARGX

$ZLAB

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $ARGX alert in real time by email

First and only NMPA-approved subcutaneous (SC) injectable providing additional flexibility and optionality for gMG patients in China
Consistent clinical benefit and safety profile of efgartigimod SC compared to IV demonstrated in Phase 3 ADAPT-SC study

Get the next $ARGX alert in real time by email

Crush Q1 2026 with the Best AI Superconnector

Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

AI-Powered Inbox

Context-aware email replies

Strategic Decision Support

Get Started with Standout.work

Recent Analyst Ratings for
$ARGX
$ZLAB

Company	Date	Price Target	Rating	Analyst
argenx SE $ARGX	12/18/2025	$858.00	Outperform → Neutral	Robert W. Baird
argenx SE $ARGX	11/24/2025		Outperform → Peer Perform	Wolfe Research
argenx SE $ARGX	9/15/2025	$918.00	Buy	Truist
argenx SE $ARGX	9/11/2025		Buy → Hold	Deutsche Bank
Zai Lab Limited $ZLAB	8/25/2025	$52.00	Buy	Jefferies
argenx SE $ARGX	8/25/2025	$850.00	Outperform	RBC Capital Mkts
argenx SE $ARGX	7/8/2025		Hold → Buy	Deutsche Bank
argenx SE $ARGX	7/3/2025	$700.00	Overweight	Morgan Stanley

More analyst ratings

Zai Lab And argenx Get Approval For Efgartigimod Alfa SC Injection For Generalized Myasthenia Gravis In China

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$ARGX
$ZLAB

Zai Lab And argenx Get Approval For Efgartigimod Alfa SC Injection For Generalized Myasthenia Gravis In China

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$ARGX
$ZLAB

$ARGX
$ZLAB
Analyst Ratings

argenx downgraded by Robert W. Baird with a new price target

argenx downgraded by Wolfe Research

Truist resumed coverage on argenx with a new price target

$ARGX
$ZLAB
Press Releases

argenx to Report Full Year 2025 Financial Results and Fourth Quarter Business Update on February 26, 2026

Zai Lab to Announce Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates on February 26, 2026

$207B Market Shift: The Race for Fast Track Approval in Oncology

$ARGX
$ZLAB
SEC Filings

SEC Form SCHEDULE 13G filed by Zai Lab Limited

Amendment: SEC Form SCHEDULE 13G/A filed by Zai Lab Limited

Amendment: SEC Form SCHEDULE 13G/A filed by Zai Lab Limited

$ARGX
$ZLAB
Insider Purchases

Officer Smiley Joshua L bought $289,100 worth of American Depositary Shares (10,000 units at $28.91), increasing direct ownership by 13% to 86,604 units (SEC Form 4)

Smiley Joshua L bought $64,200 worth of American Depositary Shares (3,000 units at $21.40), increasing direct ownership by 10% to 31,684 units (SEC Form 4)

Smiley Joshua L bought $62,490 worth of American Depositary Shares (3,000 units at $20.83), increasing direct ownership by 15% to 23,527 units (SEC Form 4)

$ARGX
$ZLAB
Insider Trading

Officer Amado Rafael sold $188,039 worth of American Depositary Shares (10,787 units at $17.43) and converted options into 21,000 units of American Depositary Shares, increasing direct ownership by 24% to 52,391 units (SEC Form 4)

Chief Legal Officer Edmondson Frazor Titus Iii sold $148,278 worth of American Depositary Shares (8,651 units at $17.14), decreasing direct ownership by 31% to 19,086 units (SEC Form 4)

Chairperson & CEO Du Ying gifted 303,378 units of American Depositary Shares and received a gift of 377,520 units of American Depositary Shares, increasing direct ownership by 8% to 964,161 units (SEC Form 4)

$ARGX
$ZLAB
Financials

argenx to Report Full Year 2025 Financial Results and Fourth Quarter Business Update on February 26, 2026

Zai Lab to Announce Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates on February 26, 2026

argenx Reports Third Quarter 2025 Financial Results and Provides Business Update

$ARGX
$ZLAB
Leadership Updates

argenx Announces Leadership Transition Marking Next Evolution of Growth

The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners

Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D

$ARGX
$ZLAB
Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by argenx SE

SEC Form SC 13G filed by Zai Lab Limited

Amendment: SEC Form SC 13G/A filed by argenx SE

Zai Lab And argenx Get Approval For Efgartigimod Alfa SC Injection For Generalized Myasthenia Gravis In China

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $ARGX$ZLAB

Zai Lab And argenx Get Approval For Efgartigimod Alfa SC Injection For Generalized Myasthenia Gravis In China

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $ARGX$ZLAB

$ARGX$ZLAB Analyst Ratings

argenx downgraded by Robert W. Baird with a new price target

argenx downgraded by Wolfe Research

Truist resumed coverage on argenx with a new price target

$ARGX$ZLAB Press Releases

argenx to Report Full Year 2025 Financial Results and Fourth Quarter Business Update on February 26, 2026

Zai Lab to Announce Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates on February 26, 2026

$207B Market Shift: The Race for Fast Track Approval in Oncology

$ARGX$ZLAB SEC Filings

SEC Form SCHEDULE 13G filed by Zai Lab Limited

Amendment: SEC Form SCHEDULE 13G/A filed by Zai Lab Limited

Amendment: SEC Form SCHEDULE 13G/A filed by Zai Lab Limited

$ARGX$ZLAB Insider Purchases

Officer Smiley Joshua L bought $289,100 worth of American Depositary Shares (10,000 units at $28.91), increasing direct ownership by 13% to 86,604 units (SEC Form 4)

Smiley Joshua L bought $64,200 worth of American Depositary Shares (3,000 units at $21.40), increasing direct ownership by 10% to 31,684 units (SEC Form 4)

Smiley Joshua L bought $62,490 worth of American Depositary Shares (3,000 units at $20.83), increasing direct ownership by 15% to 23,527 units (SEC Form 4)

$ARGX$ZLAB Insider Trading

Officer Amado Rafael sold $188,039 worth of American Depositary Shares (10,787 units at $17.43) and converted options into 21,000 units of American Depositary Shares, increasing direct ownership by 24% to 52,391 units (SEC Form 4)

Chief Legal Officer Edmondson Frazor Titus Iii sold $148,278 worth of American Depositary Shares (8,651 units at $17.14), decreasing direct ownership by 31% to 19,086 units (SEC Form 4)

Chairperson & CEO Du Ying gifted 303,378 units of American Depositary Shares and received a gift of 377,520 units of American Depositary Shares, increasing direct ownership by 8% to 964,161 units (SEC Form 4)

$ARGX$ZLAB Financials

argenx to Report Full Year 2025 Financial Results and Fourth Quarter Business Update on February 26, 2026

Zai Lab to Announce Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates on February 26, 2026

argenx Reports Third Quarter 2025 Financial Results and Provides Business Update

$ARGX$ZLAB Leadership Updates

argenx Announces Leadership Transition Marking Next Evolution of Growth

The Institute for Follicular Lymphoma Innovation (IFLI) Appoints Innovative Leaders Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners

Zai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D

$ARGX$ZLAB Large Ownership Changes

Amendment: SEC Form SC 13G/A filed by argenx SE

SEC Form SC 13G filed by Zai Lab Limited

Amendment: SEC Form SC 13G/A filed by argenx SE

Recent Analyst Ratings for
$ARGX
$ZLAB

Recent Analyst Ratings for
$ARGX
$ZLAB

$ARGX
$ZLAB
Analyst Ratings

$ARGX
$ZLAB
Press Releases

$ARGX
$ZLAB
SEC Filings

$ARGX
$ZLAB
Insider Purchases

$ARGX
$ZLAB
Insider Trading

$ARGX
$ZLAB
Financials

$ARGX
$ZLAB
Leadership Updates

$ARGX
$ZLAB
Large Ownership Changes